NLRP3 and migraine disorder: These approaches have revealed a key contribution of NLRP3 to migraine, with MCC950, a specific NLRP3 antagonist, reducing periorbital and hind paw mechanical hypersensitivity and reversing increased expression of IL-1β in trigeminal ganglia (He et al., 2019).